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ABSTRACT 
Objective: The aim of the present study was to obtain an optimized formula of itraconazole (ITC) proniosomes using Box Behnken design. 
Methods: Itraconazole proniosomes were prepared using span 60 and/or brij 35 as surfactants, cholesterol and lecithin as a penetration enhancer 
by slurry method. Various trials have been carried out for investigation of proniosomes. Parameters such as entrapment efficiency (EE%), in vitro 
drug release, zeta potential, vesicle size and Transmission Electron Microscope were assessed for evaluation of proniosomes. 
Results: Entrapment efficiency (EE%) was found to be between 78.56% and 95.46%. The release profile of itraconazole proniosomes occurred in 
two distinct phases, an initial phase for about 8 h, followed by a slow phase for 16 h. The release pattern shown by these formulations was Higuchi 
diffusion controlled mechanism. The zeta potential values for all itraconazole proniosomes were in the range of-21.71 to-34.53 mV which confirms 
their stability. All itraconazoleproniosomes formula was found to be nano-sized and were appeared to be spherical in shape with sharp boundaries. 
One way analysis of variance (ANOVA) study showed that HLB (X1) had the main effects on most responses (Y). 
Conclusion: Box behnken design facilitates optimization of the formulation ingredients on entrapment efficiency, in vitro release of itraconazole 
proniosomes, zeta potential and vesicle size. Finally, an optimum level of factors was provided by the optimization process. 
Keywords: Box behnken design, Proniosomes, Entrapment efficiency (EE%), Itraconazole (ITC), Optimization 




In recent years, considerable attention has been focused on the 
development of a new drug delivery system (NNDS). Among them 
vesicular particulate carrier is of much importance. Various type 
vesicular particulate drug delivery systems include liposomes, 
niosomes, transferosomes, ethosomes and cubosomes [1]. Niosomes 
have been evaluated in many pharmaceutical applications due to 
their important advantages to reduce the systemic toxicity by 
encapsulation of treatment agents and show slow drug release [2]. 
The approaches like provesicular drug delivery like proniosomes 
have also been developed which have better stabilities in 
comparison to simple vesicular drug delivery systems. Proniosomes 
were developed as a promising drug delivery system to counteract 
the stability problems associated with niosomes (degradation by 
hydrolysis or oxidation and sedimentation, aggregation, or fusion 
during storage) [3]. Proniosomes are dry, free-flowing and granular 
products which upon addition of water, disperses or dissolves to 
form a multilamellar noisome suspension suitable for 
administration by oral or other routes. Itraconazole (ITC) is a broad 
spectrum antifungal agent and belongs to triazole group that can be 
indicated for the treatment of local and systemic fungal infections 
[4]. Itraconazole is weakly basic (pka 3.7) and highly hydrophobic. 
The mechanism of action of itraconazole is impairing the synthesis 
of ergosterol, an essential component of the fungal cell membrane 
[5]. Optimization is the search for a result that is the best possible 
within a limited field of search, so the type and components of a 
formulation can be selected according to previous experience [6]. In 
the present study, an attempt was made to develop, optimize and 
evaluate itraconazole proniosomes using selected surfactants and 
studying theirs in vitro properties. 
MATERIALS AND METHODS 
Materials 
Itraconazole (ITC), span 60, brij 35, cholesterol and mannitol was 
purchased from Sigma Chemical Company, (USA), soya lecithin 
phospholipon 90 H was kindly donated by Lipoid (Lipoid, Germany), 
methanol, chloroform, sodium hydroxide, potassium dihydrogenortho 
phosphate were purchased from El-Nasr Chemical Company, (Cairo, 
Egypt). All other chemicals used were of analytical grade. 
Methods  
Preparation of itraconazoleproniosomes 
Proniosomes were prepared by the slurry method using three 
variables include HLB (X1), a surfactant to cholesterol ratio (X2) and 
a ratio of lecithin (X3). These variables were studied with a fifteen 
box behnken design [Statgraphics®plus (version 4), Manugistics Inc., 
Rockville, MD, USA) software]. Mixed span 60 [HLB 4.7] and brij 35 
[HLB 17] surfactants were used in different HLB values which were 
calculated according to the equation:  
% brij 35 = [RHLB-HLBlow]/[HLBhigh-HLBlow]. 
The required weight of a surfactant (span-60 and/or brij 35), 
cholesterol and drug was dissolved in chloroform: methanol (1:1) 
solution then was poured in a 100 ml round bottom flask containing 
mannitol as a carrier. The flask was attached to a rotary evaporator 
[Buchi Rotavapor R-3000, (Switzerland)] to remove solvent at 60 
rpm, using a temperature of 45 °C±2, and a reduced pressure of 600 
mmHg until the mass in the flask had become a dry product. The 
obtained proniosomes were further dried overnight in a desiccator 
at room temperature [7]. 
Micromeritics properties of proniosomes' powders 
The flow properties of itraconazole proniosomes are vital in 
handling and processing operations. The flow properties were 
studied through measuring the Angle of repose, Carr’s 
compressibility index and Hausner’s ratio. The angle of repose was 
determined by using conventional fixed funnel method. The Carr’s 
compressibility index and Hausner’s ratio were calculated from the 
bulk and tapped density of the proniosomes powders [1]. 
Db = Wt/bulk volume = W/Vb 
Dt = Wt/tap volume = W/Vt 
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Hausner ratio = D t/D b 
Compressibility % = (D t–D b/D t) × 100 
Angle of repose Tan Ө = h/r  
Entrapment efficiency of itraconazole proniosomes 
Hydrated itraconazole proniosomal dispersions were allowed to 
sediment using a centrifuge at 15000 rpm for 45 min. The 
supernatant liquid was separated, diluted to 100 ml with phosphate 
buffer pH 7.4, filtered using a membrane filter (0.45 µm pore size), 
and measured using a UV spectrophotometer [Model UV-1601PC 
Shimadzu, Japan] at a predetermined wavelength of 262.5 nm which 
was in good agreement with [Sampathi et al., 2015] [8]. The 
entrapment efficiency of itraconazole was calculated as follows:  
 
In vitro release of itraconazole 
This study was carried out using a USP dissolution tester 
[Dissolution apparatus, Erweka GmbH, Germany]. Itraconazole 
niosomal dispersion (equivalent to 5 mg drug) was transferred to 
cylindrical tubes (2.5 cm in diameter and 6 cm in length). Each tube 
was tightly covered with a molecular porous membrane from one 
end and attached to the shafts of the USP Dissolution apparatus from 
the other end. The shafts were then lowered to the vessels 
containing 250 ml of phosphate buffer (pH 7.4) at 37±0.5 °C, and 
100 rpm. Five ml samples were withdrawn at time intervals of 1, 2, 
3, 4, 6, 8, 12, and 24 h followed by replacement with fresh medium. 
The samples were analyzed spectrophotometrically at 262.5 nm. 
The obtained data were subjected to kinetic treatment, according to 
zero, first, and Higuchi diffusion models [9]. The correlation 
coefficient (r) was determined in each case. 
Zeta potential determination 
Particle sizing systems were used in the determination of zeta 
potential of all formulations. The formulations were hydrated with 
distilled water and then converted to niosomes; the formed 
niosomes were used to determine the zeta potential by using 
Particle Sizing System, Inc. Santa Barbara [10]. 
Vesicle size analysis 
This is performed for characterization of vesicle’s size. The 
proniosomal powders were hydrated with phosphate buffer (pH 
7.4) and subjected to bath sonication for 1 min and the resulting 
dispersion was used for the determination of size. Vesicle sizes of 
niosomes were determined by using Particle Sizing System, Inc. 
Santa Barbara [1]. 
Statistical analysis 
The significance of estimation was determined by ANOVA followed 
by Student’s test. 
Optimization of the formulation ingredients 
Box behnken design is independent quadratic design in that it doesn’t 
contain an embedded factorial design. In this design, the treatment 
combinations are at the midpoints of the edges of the process space. 
These designs are rotatable and require 3 levels of each factor, thus 
helping in optimizing a process using a small number of experimental 
runs [11]. The model constructed was as follows; Y = 
a0+a1X1+a2X2+a3X3+a4X1X2+a5X2X3+a6X1X3+a7X12+a8X2²+a9 X3²-------------
-+E. Where a0 to a9 are the regression coefficient, X1, X2 and X3 are the 
factors studied, Y is the measured response associated with each 
factor level combination and E is the error term. Optimization was 
performed to obtain the levels of X1, X2 and X3, which give optimum 
values of Y1, Y2, Y3 and Y4 at constrained conditions. 
Formulation of the optimized formula  
The preparation, entrapment efficiency, in vitro release, the kinetic 
study, zeta potential determination and vesicle size (as described 
before) of the optimized formula were studied and the optimized 
formula was then characterized by transmission electron eicroscope 
[TEM Jeol-200 CX, Japan] and scanning electron microscope [SEM, S-
4100, Hitachi, Japan]. 
RESULTS AND DISCUSSION 
Preparation of itraconazole proniosomes 
Three different variables include: HLB (X1), a surfactant to 
cholesterol ratio (X2) and a ratio of lecithin (X3) as shown in the table 
(1) were screened using box behnken design and fifteen different 
formulae of itraconazole proniosomes were obtained as shown in 
the table (2). In this perspective, proniosome approach has resolved 
many stability issues pertaining to aqueous noisome dispersions. 
(HLB) is a good indicator of the vesicle-forming ability of any 
surfactant. With the Sorbitan surfactants (span), an HLB number of 
between 4 and 8 was found to be compatible with vesicle formation 
[12]. The morphology and stability of the niosomes are mainly 
dependent on the concentration of nonionic surfactant and 
cholesterol and any alteration in their composition leads to 
disruption of vesicles, which leads to leakage of the free drug before 
the drug diffusion and fusion of vesicles with the gastrointestinal 
membrane. A parameter like the ratio of lecithin is a good indicator 
of membrane stabilization. 
Micromeritics properties of proniosomes' powders 
Our results indicated the small angle of repose of prepared 
itraconazole proniosomes ranged from 12.4 ° for F13 to 21 ° for F7 
assuring excellent flow properties. In addition to the angle of repose, 
Carr’s index showed a maximum value of 17.5% and the minimum 
one of 8.4% and Hausner’s ratio were also less than 1.25 ensuring an 
acceptable flow for proniosomes powder formulations. These results 
were in good agreement with Fayed et al., [2016] who estimated the 
Carr’s index of permeation proniosomes preparations which showed 
good flowability [13]. 
Entrapment efficiency of itraconazole proniosomes 
The range of the entrapment efficiency of the prepared proniosomes 
was found to be between 78.56 % for F6 and 95.46 % for F13 as 
shown in fig. (1). Fig. (2: A-H) showed the effect of the different 
independent variables on the entrapment efficiency of itraconazole 
using STRATIGRAPHIC plus computer program. By increasing (X1); 
entrapment efficiency decreased from 94.43 to 85.48 %, while by 
increasing (X2); entrapment efficiency, increased from 87.31 to 
92.79 % and by increasing (X3); entrapment efficiency increased 
from 85.15 to 89.16 %. This could be explained on the basis that the 
vesicle formation ability of hydrophobic non-ionic surfactants could 
be understood as the molecule geometry fulfilled a proper critical 
packing parameter where the highly lipophilic drug is expected to be 
housed almost completely within the vesicles bilayer [14]. Another 
possible explanation of these findings is related to the ability of 
cholesterol to be intercalated into the bilayers, thereby preventing the 
leakage of the drug through the bilayers. Moreover, the addition of 
lecithin increased the system stability due to the high transition 
temperature of hydrogenated lecithin (48 °C) and its unique 
advantage over unhydrogenated one in enhancing the rigidifying effect 
of cholesterol and formation of less leaky membrane bilayers [15]. 
Our results were inconsistent with Acharya et al., [2016] who 
showed the highest entrapment efficiency of candesartan cilexetil 
proniosomes when using span 60 due to its ability to entrap the 
drug because of longer saturated alkyl chain which lower HLB value. 
Also, the highest entrapment efficiency was shown in a formulation 
containing span 60: cholesterol in ratio 2:1. The reason for that was 
as cholesterol content of the formulation was increased, entrapment 
efficiency of the drug was also increased. As the use of cholesterol in 
the proniosomal formulations not only improves the fluidity but also 
improves the stability of the bilayer membrane because entrapment 
efficiency of niosome was governed by the ability of the formulation 
to retain drug molecules in the bilayer membrane of the vesicles. 
This characteristic of cholesterol decreases leakage of the drug 
molecule from the bilayer structure and also provides a spherical 
smooth surface to the bilayer vesicles. However, a further increase 
in cholesterol level lowers the drug entrapment efficiency of bilayer 
vesicles formulation. This could be due to the fact that the 
cholesterol beyond a certain level starts disrupting the regular 
bilayer structure of vesicles leading to loss of drug entrapment [16]. 
Mortagi et al. 
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Table 1: Formulation factors in Box behnken design 
Independent factors Low High 
X1= HLB 4.7 17 
X2= Surfactant to cholesterol ratio 1:1 2:1 
X3= Ratio of lecithin 0 1 
 
Table 2: The designed formulae of itraconazole proniosomes 
Formula No. X1 X2 X3 
F1 10.85 1:1 1 
F2 10.85 1:1 0 
F3 17 1:1 0.5 
F4 17 2:1 0.5 
F5 10.85 1.5:1 0.5 
F6 17 1.5:1 0 
F7 4.7 1:1 0.5 
F8 10.85 2:1 0 
F9 10.85 1.5:1 0.5 
F10 4.7 1.5:1 0 
F11 4.7 2:1 0.5 
F12 10.85 1.5:1 0.5 
F13 4.7 1.5:1 1 
F14 10.85 2:1 1 
F15 17 1.5:1 1 
 
 
Fig. 1: Entrapment efficiency of itraconazole proniosomes, data’s are expressed as mean±SD (n=3) 
 
 
Fig. 2: [A] Standardized pareto chart for entrapment efficiency 
 
 
Fig. 2: [B] Three-dimensional contour plot for the effect of X1 and X2 on entrapment efficiency of itraconazole proniosomes 
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Fig. 2: [C] Two-dimensional contour plot for the effect of X1 and 
X2 on entrapment efficiency of itraconazole proniosomes 
 
 
Fig. 2: [D] Three-dimensional contour plot for the effect of X1 
and X3 on entrapment efficiency of itraconazole proniosomes 
 
 
Fig. 2: [E] Two-dimensional contour plot for the effect of X1 and 
X3 on entrapment efficiency of itraconazole proniosomes 
 
 
Fig. 2: [F] Three-dimensional contour plot for the effect of X2 
and X3 on entrapment efficiency of itraconazole proniosomes 
 
 
Fig. 2: [G] Two-dimensional contour plot for the effect of X2 and 
X3 on entrapment efficiency of itraconazole proniosomes 
 
Fig. 2: [H] Main effect plot showing the effect of X1, X2 and X3on Y1 
 
In vitro release of itraconazole 
Fig. (3-5) showed the release profiles of from the prepared niosomes 
which were occurring in two distinct phases, an initial phase in 
which rapid drug leakage was observed and stayed for about 8 h, 
followed by slow phase continued for 16 h. The initial phase was due 
to desorption of the drug from the surface of niosomes while the 
drug release in the slow phase was regulated by diffusion through 
the swollen niosomal bilayers and breakage of polymers [17]. This 
was inconsistent with Abdelbary et al., [2017] who found that the 
release profiles of ketoconazole from the different prepared 
proniosomal gel formulae were found to be biphasic release, A rapid 
drug leakage was observed in the initial phase, where about 25–55 
% of the entrapped drug was released within the first few hours, 
while in the second phase, a slow release of the drug was observed 
from the different proniosomal formulations [18]. But, this was not 
inconsistent with Kumar et al., [2017] who found that the release of 
Cefixime from niosomal suspension occurred slowly and later 
immediate release due to penetration enhancement of nonionic 
surfactant [19]. 
From fig. (6: A-H), it was concluded that; the rate of release was 
decreased as (X1) increased. Although the general features of the 
release profile of the proniosomes derived niosomes prepared using 
conventional surfactants revealed significant increase (p<0.01) in 
the percentage drug released with the increase in HLB since 
hydrophilic surfactants have higher solubilizing power on 
hydrophobic solutes in aqueous medium compared to hydrophobic 
surfactants but presence of cholesterol and lecithin resulted in a 
more intact lipid bilayer which acts as a barrier for drug release, so 
decreased its leakage and permeability, hindered the release of 
entrapped drug from the vesicles and led to a significant slow 
release profile [15]. Also, the presence of double bonds in 
phosphatidylcholine allow the chain bend (undergo conformational 
rotation to give cis/transforms); so the adjacent molecule was not 
tightly close enough, when they assemble with non-ionic surfactants, 
lead to the formation of the more permeable bilayer. If the 
saturation of double bond occurs, it forces the bilayer molecules to 
get arranged to form a less permeable bilayer. 
The rate of release was increased with increasing (X2). This could be 
due to the emulsification effect of the surfactant after the hydration 
of the noisome by the dissolution medium [20]. The release rate of 
itraconazole niosomes was increased till ratio of lecithin become 0.5 
then decreased; this was because of factors that stabilize the vesicle 
membrane and increase the entrapment efficiency of a hydrophobic 
drug as itraconazole will slow down the release profile [15]. 
As shown in the table (3) the best kinetic order for the in vitro 
release of itraconazole was calculated from the highest values of the 
obtained correlation coefficients. The kinetic analysis of all release 
profiles followed diffusion controlled mechanism. Our results were 
in good agreement with Arafa et al., [2017] who found that the 
release profile of salbutamol sulphate from niosomes followed 
Higuchi model. This kinetic pattern indicated that the drug release 
was dominated by diffusion model which normally depended on 
drug concentration gradient between nano-vesicles and dissolution 
media with penetration of this media through a porous wall which 
accompanied by matrix disruption [21]. 
Mortagi et al. 




Fig. 3: In vitro release of itraconazoleniosome (F1-F5), data’s are expressed as mean±SD (n=3) 
 
 
Fig. 4: In vitro release of itraconazole noisome (F6-F10), data’s are expressed as mean±SD (n=3) 
 
 
Fig. 5: In vitro release of itraconazole niosome (F11-F15), data’s are expressed as mean±SD (n=3) 
 
 
Fig. 6: [A] Standardized Pareto chart for in vitro release of itraconazole 
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Fig. 6: [B] Three-dimensional contour plot for the effect of X1 
and X2 on in vitro release of itraconazole 
 
 
Fig. 6: [C] Two-dimensional contour plot for the effect of X1 and 
X2 on in vitro release of itraconazole 
 
 
Fig. 6: [D] Three-dimensional contour plot for the effect of X1 
and X3 on in vitro release of itraconazole 
 
Fig. 6: [E] Two-dimensional contour plot for the effect of X1 and 
X3 on in vitro release of itraconazole 
 
 
Fig. 6: [F] Three-dimensional contour plot for the effect of X2 
and X3 on in to release of itraconazole 
 
 
Fig. 6: [G] Two-dimensional contour plot for the effect of X2 and 
X3 on in vitro release of itraconazole 
 
Table 3: The calculated correlation coefficients for the in vitro release of itraconazole pronoisomes employing different kinetic orders or 
systems 
Formula no. Correlation coefficient (r) 
Zero First Diffusion 
F1 0.904301 -0.9386 0.959002 
F2 0.799789 -0.87456 0.904464 
F3 0.879075 -0.92175 0.947736 
F4 0.807341 -0.88858 0.904602 
F5 0.867504 -0.9301 0.947083 
F6 0.674383 -0.74769 0.807225 
F7 0.89308 -0.9282 0.951535 
F8 0.708502 -0.76919 0.836356 
F9 0.862389 -0.93302 0.945036 
F10 0.821331 -0.91377 0.9176623 
F11 0.839682 -0.92118 0.928696 
F12 0.864263 -0.92011 0.945363 
F13 0.882462 -0.93021 0.949866 
F14 0.875488 -0.92938 0.950812 
F15 0.918642 -0.9486 0.962218 
 
Vesicle size analysis 
The results revealed that all the prepared hydrated proniosomes 
showed a considerable small vesicle size. The mean vesicle size of 
hydrated proniosome dispersions ranged from 286.6±(0.588) nm 
(F10) to 697.5±(0.834) nm (F4). The polydispersity index, PDI, 
which is the measure of particle homogeneity and it varies from 0.0 
to 1.0. PDI of itraconazole proniosomes formulations ranged from 
0.334 to 0.819. These low values contributed to relatively narrow 
size distribution and homogenous distribution [25].  
Fig. (8: A-H) showed the effect of the different independent 
variables on vesicle size of itraconazole proniosomes. By 
increasing (X1); the vesicle size increased due to the direct 
proportionality did exist between the vesicle size and both chain 
length and degree of hydrophilicity of the surfactants forming the 
vesicle bilayer [26]. While increasing (X2) resulted in firstly 
decreasing vesicle size then increased. The decrease in the size 
firstly was because of a decrease in cholesterol content relative to 
a surfactant which contributed to increase the hydrophobicity 
then further increase in surfactant/lipid ratio led to an increase in 
vesicle size which was substantiated by the increase in the overall 
degree of hydrophilicity [27]. Also, increasing lecithin content (X3) 
led to increase in mean vesicle size because of the long 
hydrocarbon chain of lecithin molecules (18C) [15]. 
Mortagi et al. 
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The same results were recorded by Ashmoony et al., [2014] who 
observed the nano-size range of Clomipramine niosomes. Also, by 
analysis of particle size results, they found as the concentration of 
cholesterol was increased, the particle size of different formulations also 








Fig. 7: [B] Three-dimensional contour plot for the effect of X1 
and X2 on zeta potential of itraconazole proniosomes 
 
 
Fig. 7: [C] Two-dimensional contour plot for the effect of X1 and 
X2 on the zeta potential of itraconazole proniosomes 
 
 
Fig. 7: [D] Three-dimensional contour plot for the effect of X1 
and X3 on zeta potential of itraconazole proniosomes 
 
 
Fig. 7: [E] Two-dimensional contour plot for the effect of X1 and 
X3 on the zeta potential of itraconazole proniosomes 
 
Fig. 7: [F] Two-dimensional contour plot for the effect of X2 and 
X3 on the zeta potential of itraconazole proniosomes 
 
 
Fig. 7: [G] Three-dimensional contour plot for the effect of X1 
and X3 on zeta potential of itraconazole proniosomes 
 
 








Fig. 8: [B] Three-dimensional contour plot for the effect of X1 
and X2 on vesicle size of itraconazole proniosomes 
 
 
Fig. 8: [C] Two-dimensional contour plot for the effect of X1 and 
X2 on vesicle size of itraconazole proniosomes 
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Fig. 8: [D] Three-dimensional contour plot for the effect of X1 
and X3 on vesicle size of itraconazole proniosomes 
 
 
Fig. 8: [E] Two-dimensional contour plot for the effect of X1 and 
X3 on vesicle size of itraconazole proniosomes 
 
 
Fig. 8: [F] Three-dimensional contour plot for the effect of X2 
and X3 on vesicle size of itraconazole proniosomes 
 
Fig. 8: [G] Two-dimensional contour plot for the effect of X2 and 
X3 on vesicle size of itraconazole proniosomes 
 
 
Fig. 8: [H] Main effect plot showing the effect of X1, X2 and X3 on Y4 
 
Statistical analysis  
Tables (4-7) explained the one-way analysis of variance (ANOVA), 
which partitions the variability in Y1, Y2, Y3 and Y4 into separate 
pieces for each of the effects. Then, it tests the statistical significance 
of each effect through comparing the mean square against an 
estimate of the experimental error. The effects of all the tested 
independent variables have a P-values less than 0.05, indicating that 
they are significantly different from zero at 95% confidence level. 
 
Table 4: Analysis of variance for entrapment efficiency (Y1) 
Source Sum of squares DF Mean square F-Ratio P-Value 
A: (X1) 160.384 1 160.384 8.97 0.0303 
B: (X2) 59.9513 1 59.9513 3.35 0.1266 
C: (X3) 32.08 1 32.08 1.79 0.2381 
AA 0.08169 1 0.08169 0.00 0.9487 
AB 2.7722 1 2.772 0.16 0.7100 
AC 0.00002 1 0.00002 0.00 0.9991 
BB 0.01066 1 0.01066 0.00 0.9815 
BC 0.4970 1 0.4970 0.03 0.8741 
CC 32.1051 1 32.1051 1.80 0.2379 
Total error 89.4006 5 17.8801   
Total (correlation) 377.318 14    
R-squared (76.3063) %; R-squared (adjusted for DF) (33.6576) %; Standard Error of Est.(4.2284); Mean absolute error (2.02); Durbin-Watson statistic 
(1.62882). 
 
Table 5: Analysis of variance for in vitro release of itraconazole after 24 h (Y2) 
Source Sum of squares DF Mean square F-Ratio P-Value 
A: (X1) 70.9836 1 70.9836 26.54 0.0036 
B: (X2) 8.3232 1 8.3232 3.11 0.1380 
C: (X3) 0.0105 1 0.01051 0.00 0.9524 
AA 8.3863 1 8.38634 3.14 0.1368 
AB 4.4521 1 4.4521 1.66 0.2534 
AC 11.7306 1 11.7306 4.39 0.0904 
BB 50.014 1 50.014 18.70 0.0075 
BC 45.5625 1 45.5625 17.04 0.0091 
CC 43.3869 1 43.3869 16.22 0.0100 
Total error 13.3717 5 2.67434   
Total (correlation) 256.337 14    
R-squared (94.7836) %; R-squared (adjusted for DF) (85.394) %; Standard Error of Est. (1.63534); Mean absolute error (0.793222); Durbin-
Watson statistic (2.33819). 
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Table 6: Analysis of variance for zeta potential (Y3) 
Source Sum of squares DF Mean square F-Ratio P-Value 
A: (X1) 30.381 1 30.381 1.98 0.2187 
B: (X2) 6.53411 1 6.53411 0.43 0.5431 
C: (X3) 10.0352 1 10.0352 0.65 0.4557 
AA 5.247 1 5.247 0.34 0.5843 
AB 0.011025 1 0.011025 0.00 0.9797 
AC 14.0625 1 14.0625 0.92 0.3827 
BB 4.90079 1 4.90079 0.32 0.5966 
BC 0.3481 1 0.3481 0.02 0.8862 
CC 9.106 1 9.106 0.59 0.4762 
Total error 76.8276 5 15.3655   
Total (correlation) 158.898 14    
R-squared (51.6498) %; R-squared (adjusted for DF) (0) %; Standard Error of Est. (3.91989); Mean absolute error (1.92244); Durbin-Watson 
statistic (1.68279). 
 
Table 7: Analysis of variance for vesicle size (Y4) 
Source Sum of squares DF Mean square F-Ratio P-Value 
A: (X1) 227948.0 1 227948.0 823.48 0.0000 
B: (X2) 1794.01 1 1794.01 6.48 0.0515 
C: (X3) 5222.42 1 5222.42 18.87 0.0074 
AA 19728.0 1 19728.0 71.27 0.0004 
AB 13.3225 1 13.3225 0.05 0.8350 
AC 3642.12 1 3642.12 13.16 0.0151 
BB 3558.81 1 3558.81 12.86 0.0158 
BC 1235.52 1 1235.52 4.46 0.0883 
CC 4933.69 1 4933.69 17.82 0.0083 
Total error 13.84.06 5 276.811   
Total (correlation) 270593.0 14    
R-squared (99.4885) %; R-squared (adjusted for DF) (98.5678) %; Standard Error of Est. (16.6376); Mean absolute error (8.13556); Durbin-
Watson statistic (1.36368). 
 
Optimization of the formulation ingredients 
The dependent and independent variables were related using 










The equation represents the effect of process variables (X1, X2 and 
X3) on the responses (Y1, Y2, Y3 and Y4). Here, variables X2, X3 and 
X1X3 have positive effects on entrapment efficiency as revealed by 
the positive value of coefficients in the equation, it means that as the 
ratio of surfactant to cholesterol (X2) and a ratio of lecithin (X3) 
increases, entrapment efficiency increases. Whereas X1, (X1)2, X1X2, 
(X2)2, X2X3 and (X3)2 have negative effects on entrapment efficiency 
as revealed by negative values of the coefficient in equation 1, it 
means that as HLB (X1) increases, entrapment efficiency decreases. 
Variables X2, X3, (X1)2 and X1X2 have positive effects on in vitro 
release as revealed by the positive value of coefficients in the 
equation. While X1, X1X3, (X2)2, X2X3 and (X3)2 have negative effects on 
in vitro release as revealed by negative values of the coefficient in 
equation 2. Also, variables X1, X2, X3 and (X3)2 with positive effects 
on zeta potential assigned by positive value of coefficients in the 
equation, but (X1)2, X1X2, X1X3, (X2)2 and X2X3 have negative effects on 
zeta potential assigned by negative values of coefficient in equation 
3. In addition to variables (X1)2, X1X3, (X2)2 and X2X3 have positive 
effects on vesicle size as revealed by the positive value of coefficients 
in the equation. While, X1, X2, X3, X1X2 and (X3)2 have negative effects 
on vesicle size as revealed by negative values of the coefficients in 
equation 4. 
These variables were optimized with a fifteen run box behnken design 
as shown in table (8), when mixing of X1 (4.7), X2 (1.721) and X3 
(0.389), predicted optimum response for entrapment efficiency 
(95.46%), for Y2 (98.5%), for Y3 (-31.44mV), and for Y4 (343.197 nm). 
 
Table 8: Optimum desirability 
Independent variables Low High Optimum 
X1 = HLB 4.7 17 4.7 
X2= Surfactant-Cholesterol ratio 1:1 2:1 1.721 




Y3 -31.44 mV 
Y4 343.19 nm 
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Formulation of the optimized formula  
The optimized formula was prepared by the slurry method. Y1 of the 
optimized formula was found to be 94.95%±0.36, while Y2 was 
98.13±2.51 %, Y3 was-30.15±0.41 mV and Y4 was 340.48±0.581 nm. 
The Kinetic models of the optimized formula were found to obey 
Higuchi’s diffusion model. 
Table (9) showed the actual and predicted effect of the optimized 
variables on different responses. Small residual values indicated that 
there was no great difference between actual and predicted values. 
Scanning electron micrographs showed the formation of 
proniosomes loaded on a mannitol carrier before hydration of the 
proniosomes and their shape were almost spherical as shown in fig. 
(9). Our results were in good agreement with Arafa et al., [2017] 
who observed salbutamol sulphate under scanning electron 
microscope and found spherical niosomes with some discontinuities 
in the membrane. This was due to the acyl-chain structure of span 
60, which could affect cholesterol interactions causing variations in 
cholesterol distribution. The polar head group of non-ionic 
surfactant must cover the non-polar portion of cholesterol; this 
coverage is essential to avoid the unfavourable free energy of 
cholesterol that when contacts with water decrease the repulsion 
between cholesterol molecules [21]. 
Transmission electron micrographs revealed the formation of well 
identified hydrated niosomal vesicles as shown in fig. (10). The 
examined niosomes appeared as spherical, nano-sized, unilamellar 
vesicles with sharp boundaries and well separated from each other 
[29]. This could be attributed to the fact that, on niosome formation 
using span, spherical shaped niosomes were obtained in order to 
minimize the surface free energy. The non-ionic surfactants form a 
closed bilayer vesicle in aqueous media based on its amphiphilic 
nature using some energy [30]. 
 
Table 9: Actual, predicted and residual values for itraconazole proniosomes optimized formula 
Response Actual values Predicted values Residual 
Y1 94.95±0.36% 95.46% -0.51 
Y2 98.13±2.51% 98.5% -0.37 
Y3 -30.15±0.41 mV -31.44 mV -1.29 
Y4 340.48±0.581 nm 343.19 nm -2.71 
Data’s are expressed as mean±SD (n=3) 
 
 
Fig. 9: Scanning electron microscope of the optimized formula 
of itraconazole proniosomes 
 
 
Fig. 10: Transmission electron microscope of the optimized 
formula of itraconazole proniosomes 
 
CONCLUSION 
In the present work, itraconazole proniosomes were prepared by 
the slurry method. Box behnken design was successfully applied to 
optimize the effect of HLB, a surfactant to cholesterol ratio and the 
ratio of lecithin on entrapment efficiency, in vitro release, zeta 
potential and vesicle size. The derived polynomial equations and 
main effect values aid in predicting the values of selected 
independent variables as 4.7 from X1, 1.721 from X2 and 0.389 from 
X3 for preparation of optimum itraconazole formulation with desired 
properties, as entrapment efficiency (Y1) of 94.95 %, in vitro release 
(Y2) of 98.13 %, zeta potential (Y3) of-30.15 mV and vesicle size (Y4) 
of 340.48 nm and these observed values of the optimized formula 
were close to the predicted values. 
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